Daiichi Sankyo begins enrolment in Phase IIIb trial of edoxaban to treat atrial fibrillation

Japanese-based pharmaceutical firm Daiichi Sankyo has begun enrolment in the Phase IIIb ENTRUST-AF PCI clinical trial of edoxaban for the treatment of atrial fibrillation patients who have undergone percutaneous coronary intervention (PCI) with stent …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news